-
Treatment outcome and compliance to dose-intensifed linac-based SBRT for unfavorable prostate tumors using a novel real-time organ-motion tracking
·
Read articleRafaella Lucchini1,2, Denis Panizza1,3, Riccardo Ray Colciago1,2* , Veronica Vernier1, Martina Camilla Daniotti4,Valeria Faccenda3,5 and Stefano Arcangeli1,2
1 Medical Physics Department, ASST Monza, Monza, Italy, 2 School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy, 3 Department of Physics, University of Milan, Milan, Italy, 4 Radiation Oncology Department, ASST Monza, Monza, Italy
-
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial
Read articlePer Fransson, PhD, Per Nilsson, PhD, Adalsteinn Gunnlaugsson, MD, Lars Beckman, MD, Björn Tavelin, BSc, David Norman, BSc, Camilla Thellenberg-Karlsson, MD, Prof Morten Hoyer, MD, Magnus Lagerlund, MD, Jon Kindblom, MD, Claes Ginman, MD, Bengt Johansson, MD, Kirsten Björnlinger, MD, Mihajl Seke, MD, Måns Agrup, MD, Prof Björn Zackrisson, MD, Elisabeth Kjellén, MD, Prof Lars Franzén, MD, Prof Anders Widmark, MD
-
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
Read articleDavid Dearnaley et al.
Publications
Here you can find a selection of peer-reviewed papers and scientific posters.
Follow us on LinkedIn
Let’s keep in touch